The role of teratology information services in screening for teratogenic exposures: Challenges and opportunities

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 157, Issue 3, 2011, Pages 195-200

  Chambers, Christina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Small cohort study; Teratology; Teratology information services

Indexed keywords

ANTIVITAMIN K; COUMARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOXETINE; LEFLUNOMIDE; LITHIUM; MISOPROSTOL; TERATOGENIC AGENT; THALIDOMIDE;

ABORTION; ADVERSE OUTCOME; ARTICLE; BIOGEOGRAPHIC REGION; BIRTH DEFECT; BIRTH WEIGHT; CASE CONTROL STUDY; CONGENITAL MALFORMATION; EMBRYO DEVELOPMENT; EMBRYOPATHY; EMBRYOTOXICITY; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERTENSION; INFORMATION SERVICE; METHODOLOGY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SAMPLE SIZE; SCREENING; SIDE EFFECT; SPONTANEOUS ABORTION; TERATOGENICITY; TERATOLOGY INFORMATION SERVICE; THIRD TRIMESTER PREGNANCY; VOLUNTEER;

ABNORMALITIES, DRUG-INDUCED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INFORMATION SERVICES; PREGNANCY; SAMPLE SIZE; TERATOGENS;

EID: 79960555796     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30303     Document Type: Article

References (17)

1. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. 1996. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010-1015.
2. Chambers CD, Braddock SR, Briggs GG, Einarson A, Johnson YR, Miller RK, Polifka JE, Robinson LK, Stepanuk K, Jones KL. 2001. Postmarketing surveillance for human teratogenicity: A model approach. Teratology 64:252-261.
3. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, Mirrasoul N, Salas E, Luo YJ, Jin S, Jones KL, Organization of Teratology Information Specialists Collaborative Research Group. 2010. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 62:1494-1503.
4. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 31:540-545.
5. Felix RJ, Jones KL, Johnson KA, McCloskey CA, Chambers CD, the Organization of Teratology Information Services (OTIS) Collaborative Research Group. 2004. Postmarketing surveillance for drug safety in pregnancy: The Organization of Teratology Information Services project. Birth Defects Res Clin Mol Teratol 70:944-947.
6. Hancock RL, Koren G, Einarson A, Ungar WJ. 2007. The effectiveness of Teratology Information Services (TIS). Reprod Toxicol 23:125-132.
7. Hancock RL, Ungar WJ, Einarson A, Goostadt M, Koren G. 2008. Providing information regarding exposures in pregnancy: A survey of North American Teratology Information Services. Reprod Toxicol 25:381-387.
8. Hancock RL, Ungar WJ, Einarson A, Koren G. 2010. International practices in the provision of teratology information: A survey of international teratogen information programmes and comparisons with the North American model. J Eval Clin Pract 16:957-963.
9. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, Donnenfeld AE, Rieder M, Santelli R, Smythe J, et al. 1992. Prospective mulicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339:530-533.
10. Johnson KA, Weber PA, Jones KL, Chambers CD. 2001. Selection bias in Teratology Information Service pregnancy outcome studies. Teratology 64:79-82.
11. Leen-Mitchell M, Martinez L, Gallegos S, Robertson J, Carey JC. 2000. Mini-review: History of organized Teratology Information Services in North America. Teratology 61:314-317.
12. Lim JM, Sullivan E, Kennedy D. 2009. MotherSafe: Review of three years of counselling by an Australian teratology Information Service. Aust N Z J Obstet Gynaecol 49:168-172.
13. Schaefer C, Hannemann D, Meister R. 2005. Post-marketing surveillance system for drugs in pregnancy-15 years experience of ENTIS. Reprod Toxicol 20:331-343.
14. Schaefer C, Hannemann D, Meister R, Elefant E, Paulus W, Vial T, Reuvers M, Robert-Gnansia E, Arnon J, De Santis M, Clementi M, Rodriguez-Pinilla E, Dolivo A, Merlob P. 2006. Vitamin K antagonists and pregnancy outcome. Throm Haemost 95:949-957.
15. Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. 2008. Using observational cohort data for studying drug effects on pregnancy outcome-Methodological considerations. Reprod Toxicol 26:36-41.
16. Schatz M, Chambers CD, Jones KL, Louik C, Mitchell AA. 2011. Safety of influenza immunizations and treatment during pregnancy: The vaccines and medications in pregnancy surveillance system. Am J Obstet Gynecol 204 (6 Suppl 1): S64-S68.
17. Schuler L, Pastuszak A, Sanseverino MTV, Orioli IM, Brunoni D, Ashton-Prolla P, Da Costa FS, Giugliana R, Couto AM, Brandao SB, Koren G. 1999. Pregnancy outcome after exposure to misoprostol in Brazil: A prospective, controlled study. Reprod Toxicol 13:147-151.